Biocentury: Regeneron Using Interleukin Antibody Receptors for Asthma Medication

An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab.

Read more »